100 related articles for article (PubMed ID: 32820684)
1. Clinical characteristics and survival of extranodal natural killer/T-cell lymphoma: a single-center 12-year retrospective analysis.
Chen Y; Luo L; Zheng X; Fu H; Yang X; Huang W; Chen L; Zheng Z; Zheng J; Yang T; Liu T; Hu J
Leuk Lymphoma; 2020 Dec; 61(14):3306-3318. PubMed ID: 32820684
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of a Pegasparaginase-Based Chemotherapy Regimen vs an L-asparaginase-Based Chemotherapy Regimen for Newly Diagnosed Advanced Extranodal Natural Killer/T-Cell Lymphoma: A Randomized Clinical Trial.
Wang X; Zhang L; Liu X; Li X; Li L; Fu X; Sun Z; Wu J; Zhang X; Yan J; Chang Y; Nan F; Zhou Z; Wu X; Tian L; Ma M; Li Z; Yu H; Zhu L; Wang Y; Shi C; Feng X; Li J; Ding M; Zhang J; Dong M; Xue H; Wang J; Zou L; Su L; Wu J; Liu L; Bao H; Zhang L; Guo Y; Guo S; Lu Y; Young KH; Li W; Zhang M
JAMA Oncol; 2022 Jul; 8(7):1035-1041. PubMed ID: 35708709
[TBL] [Abstract][Full Text] [Related]
3. CD56-Negative Extranodal Natural Killer/T-Cell Lymphoma: A Retrospective Study in 443 Patients Treated by Chemotherapy With or Without Asparaginase.
Yang J; Li P; Piao Y; Liu X; Wei L; Sang W; Zhang L; Wang L
Front Immunol; 2022; 13():829366. PubMed ID: 35371002
[TBL] [Abstract][Full Text] [Related]
4. Intensive therapy can improve long-term survival in newly diagnosed, advanced-stage extranodal NK/T-cell lymphoma: A multi-institutional, real-world study.
Wei YC; Qi F; Zheng BM; Zhang CG; Xie Y; Chen B; Liu WX; Liu WP; Fang H; Qi SN; Zhang D; Chai Y; Li YX; Wang WH; Song YQ; Zhu J; Dong M
Int J Cancer; 2023 Nov; 153(9):1643-1657. PubMed ID: 37539660
[TBL] [Abstract][Full Text] [Related]
5. Sequential P-GEMOX and radiotherapy for early-stage extranodal natural killer/T-cell lymphoma: A multicenter study.
Zhang Y; Ma S; Cai J; Yang Y; Jing H; Shuang Y; Peng Z; Li B; Liu P; Xia Z; Xia Y; Gao Y; Chen D; Lin J; Li Q; Xu S; Xu Q; Zhang H; Huang H; Cai Q
Am J Hematol; 2021 Nov; 96(11):1481-1490. PubMed ID: 34449095
[TBL] [Abstract][Full Text] [Related]
6. High-dose extended-field radiotherapy plus chemotherapy improved survival in extranodal NK/T-cell lymphoma in a real-life setting: results from the multicenter T-Cell Brazil Project.
de Pádua Covas Lage LA; Machado PPF; Reichert CO; Miranda E; Culler HF; da Siqueira SAC; de Oliveira Costa R; Miyashiro DR; Sanches JA; Rocha V; Chiattone CS; Pereira J
Sci Rep; 2022 Nov; 12(1):20557. PubMed ID: 36446856
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of PD-1 inhibitor alone or combined with chemotherapy in patients with relapsed or refractory extranodal natural Killer/T cell lymphoma: A retrospective study.
Tian J; Hao M; Liu Q; Xiao F; Li Y; Qi M; Gao J; Liu L; Yin D
Hematol Oncol; 2023 Aug; 41(3):396-406. PubMed ID: 36516297
[TBL] [Abstract][Full Text] [Related]
8. Long-term outcomes and central nervous system relapse in extranodal natural killer/T-cell lymphoma.
Miyazaki K; Suzuki R; Oguchi M; Taguchi S; Amaki J; Maeda T; Kubota N; Maruyama D; Terui Y; Sekiguchi N; Takizawa J; Tsukamoto H; Murayama T; Ando T; Matsuoka H; Hasegawa M; Wada H; Sakai R; Kameoka Y; Tsukamoto N; Choi I; Masaki Y; Shimada K; Fukuhara N; Utsumi T; Uoshima N; Kagami Y; Asano N; Ejima Y; Katayama N; Yamaguchi M
Hematol Oncol; 2022 Oct; 40(4):667-677. PubMed ID: 35142384
[TBL] [Abstract][Full Text] [Related]
9. The clinical characteristics and prognostic factors of 410 patients with natural killer/T-cell lymphoma.
Sun Z; Wan W; Zhang X; Zhang L; Li X; Li L; Wang X; Nan F; Yu H; Chang Y; Yan J; Li Z; Cui F; Ge J; XiaXu YD; Xu X; Fu X; Zhang M
J Cancer Res Clin Oncol; 2022 Dec; 148(12):3449-3459. PubMed ID: 35857124
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the clinical efficacies of two L-asparaginase-based chemotherapy regimens for newly diagnosed nasal-type extranodal NK/T-cell lymphoma.
Wu W; Ren K; Chen X; Li N; Luo Q; Hai T; Zhou H; Zou L
Cancer Med; 2023 Apr; 12(8):9458-9470. PubMed ID: 37000008
[TBL] [Abstract][Full Text] [Related]
11. Comparison analysis of first-line asparaginase- versus non-asparaginase-based regimens for early-stage extranodal NK/T-cell lymphoma.
Qi F; Xie Y; Wang D; Chai Y; Chen B; Sun Y; Liu W; Qi S; Wei Y; Fang H; Zhao D; Gui L; Yang Y; Feng X; Ding N; Mi L; Shu S; Li Y; Song Y; Dong M; Zhu J
Ann Hematol; 2022 Sep; 101(9):2021-2034. PubMed ID: 35798977
[TBL] [Abstract][Full Text] [Related]
12. [Analysis of prognostic factors of extranodal NK/T-cell lymphoma treated with pegaspargase/L-asparaginase: a multicenter retrospective study].
Shen ZY; Chen XC; Shan HR; Jia T; Gu WY; Wang F; Teng QL; Wang L; Wang CL; Shi YY; Zhang H; Miao YQ; Zhu TG; Ji CY; Ye JJ; Zhang MZ; Zhang XD; Wang L; Xu KL; Sang W
Zhonghua Xue Ye Xue Za Zhi; 2023 Aug; 44(8):642-648. PubMed ID: 37803837
[No Abstract] [Full Text] [Related]
13. Selinexor With Anti-PD-1 Antibody as a Potentially Effective Regimen for Patients With Natural Killer/T-Cell Lymphoma Failing Prior L-Asparaginase and PD-1 Blockade.
Tao R; Liu C; Zhang W; Zhu Y; Ma Y; Hao S
Oncologist; 2024 Jan; 29(1):e90-e96. PubMed ID: 37616529
[TBL] [Abstract][Full Text] [Related]
14. Combination of Anti-PD-1 Antibody, Anlotinib and Pegaspargase "Sandwich" With Radiotherapy in Localized Natural Killer/T Cell Lymphoma.
Sun P; Wang Y; Yang H; Chen C; Nie M; Sun XQ; He XH; Huang KM; Huang JJ; Li ZM
Front Immunol; 2022; 13():766200. PubMed ID: 35237257
[TBL] [Abstract][Full Text] [Related]
15. Comparison of chemotherapy with or without asparaginase for extranodal nasal NK/T-cell lymphoma in children and adolescents.
Zhen Z; Huang H; Lin T; Li Z; Zhen X; Xia Z; Zhu J; Lu S; Sun F; Wang J; Huang J; Sun X
Pediatr Blood Cancer; 2021 May; 68(5):e28901. PubMed ID: 33484107
[TBL] [Abstract][Full Text] [Related]
16. Treatment and prognosis of newly diagnosed advanced-stage extranodal natural killer / T cell lymphoma: a single-center real-world study across two decades.
Wei YC; Qi F; Chen B; Zhang CG; Fang H; Zhang D; Qi SN; Chai Y; Li YX; Dong M
Chemotherapy; 2023 Nov; ():. PubMed ID: 37984344
[TBL] [Abstract][Full Text] [Related]
17. Clinical features, prognostic stratification, and treatment of advanced-stage non-nasal type extranodal natural killer/T-cell lymphoma: a multi-institutional real-world study.
Wei YC; Liu WX; Qi F; Zhang CG; Zheng BM; Xie Y; Chen B; Zhang D; Liu WP; Fang H; Chai Y; Qi SN; Li YX; Wang WH; Song YQ; Zhu J; Dong M
Ann Hematol; 2024 Jan; 103(1):163-174. PubMed ID: 37817010
[TBL] [Abstract][Full Text] [Related]
18. Outcomes and prognostic factors of patients with Extranodal NK T cell lymphoma (ENKTL).
Rajendra A; Sengar M; Bonda VNA; Jain H; Nayak L; Thorat J; Shet T; Epari S; Laskar S; Aggarwal A; Rangarajan V; Gujral S; Bagal B; Kakoti S; Salvi O
Leuk Lymphoma; 2023 Dec; 64(12):1914-1926. PubMed ID: 37602660
[TBL] [Abstract][Full Text] [Related]
19. Outcome after hematopoietic stem cell transplantation in patients with extranodal natural killer/T-Cell lymphoma, nasal type: A French study from the Société Francophone de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC).
Philippe Walter L; Couronné L; Jais JP; Nguyen PD; Blaise D; Pigneux A; Socié G; Thieblemont C; Bachy E; Fegueux N; Chevallier P; Mohty M; Yakoub-Agha I; Peffault de Latour R; Jaccard A; Hermine O;
Am J Hematol; 2021 Jul; 96(7):834-845. PubMed ID: 33864708
[TBL] [Abstract][Full Text] [Related]
20. Combined immune checkpoint blockade and radiotherapy induces durable remission in relapsed natural killer/T-cell lymphoma: a case report and review of the literature.
McGehee E; Patel H; Pearson C; Clements K; Jaso JM; Chen W; Callan A; Desai N; Ramakrishnan Geethakumari P
J Med Case Rep; 2021 Apr; 15(1):221. PubMed ID: 33926575
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]